WONDERS1NCT06544733
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 7 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Study was terminated due to benefit and risk assessment. Show 7 more changesShow less
- Eligibility criteria shortened, about 8 words
- Primary endpoints: details revised at 2 of 2 entries
- Final enrollment: 80 participants (planned 675)
- Primary completion date changed from estimate of Jan 2028 to Nov 3, 2026
- Interventions: Bictegravir/emtricitabine/tenofovir alafenamide (Drug), Lenacapavir pacfosacil (Drug), Lepetegravir (Drug), Lepetegravir/Lenacapavir… to Bictegravir/emtricitabine/tenofovir alafenamide (Drug), Lenacapavir pacfosacil (Drug), Lepetegravir (Drug), Lepetegravir/Lenacapavir…
- Secondary endpoints: details revised at 8 of 27 entries
- Site details revised at 2 of 39 sites
- Notable Eligibility criteria expanded, about 1 word
- Interventions: Bictegravir/emtricitabine/tenofovir alafenamide (Drug), GS-1720 (Drug), GS-1720/GS-4182 FDC (Drug), GS-4182 (Drug), Placebo to Match BVY… to Bictegravir/emtricitabine/tenofovir alafenamide (Drug), Lenacapavir pacfosacil (Drug), Lepetegravir (Drug), Lepetegravir/Lenacapavir…
- Secondary endpoints revised (27)
- Study title expanded, about 5 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 36 to 39
- Minor Site details revised at 1 of 36 sitesv4
- Minor Study sites: 8 to 36v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 8
- Start date changed from estimate of Sep 2024 to Aug 20, 2024
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (27)
Show 22 moreShow less
Arms and interventions
Participants who have been virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide (BVY) will switch to lepetegravir (650 mg tablet) and lenacapavir pacfosacil (300 mg tablet) coadministered. Participants will receive a 1-day loading dose of lepetegravir (1300 mg) and lenacapavir pacfosacil (600 mg) on Day 1. Thereafter, participants will take weekly doses of single agent lepetegravir (650 mg) and lenacapavir pacfosacil (300 mg) coadministered for at least 48 weeks.
Participants who have been virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide (BVY) will continue receiving BVY daily for at least 48 weeks.
At the end of the randomized treatment, Phase 2 participants will be given the option to participate in the Extension Phase. Phase 2 Treatment Group 1 will switch to lepetegravir /lenacapavir pacfosacil FDC weekly. Phase 2 Treatment Group 2 will receive a loading dose of lepetegravir /lenacapavir pacfosacil FDC on Extension Phase Day 1 then, lepetegravir/lenacapavir pacfosacil FDC weekly. Participants who choose to enter the Extension Phase will receive lepetegravir /lenacapavir pacfosacil FDC tablets until the product becomes available or until Gilead Sciences elects to discontinue the study, whichever occurs first.
Participants who have been virologically suppressed on BVY will switch from BVY to lepetegravir/lenacapavir pacfosacil FDC tablets weekly + placebo-to-match (PTM) BVY once daily. In addition, participants will receive a 1-day loading dose regimen of lepetegravir /lenacapavir pacfosacil FDC on Day 1. Participants will receive treatment for at least 96 weeks.
Participants who have been virologically suppressed on BVY will continue receiving oral BVY daily. In addition, participants will receive a 1-day loading dose of PTM lepetegravir /lenacapavir pacfosacil on Day 1 and weekly PTM thereafter. Participants will receive treatment for at least 96 weeks.
After the end of blinded treatment, Phase 3 participants will be given the option to participate in the Extension Phase. Phase 3 Treatment Group 1 will switch to lepetegravir/lenacapavir pacfosacil FDC weekly. Phase 3 Treatment Group 2 will receive a 1-day loading dose of lepetegravir/lenacapavir pacfosacil FDC on Extension Phase Day 1, then lepetegravir/lenacapavir pacfosacil FDC weekly. Participants who choose to enter the Extension Phase will receive lepetegravir/lenacapavir pacfosacil FDC tablets until the product becomes available or until Gilead Sciences elects to discontinue the study, whichever occurs first.
Drugs: Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
Sites
39 sites in 2 countries
United States 35, Puerto Rico 4